Company: INDP
Filing Date: 2025-02-05
Form Type: S-3
Source: 0001493152-25-005016
Chunk: 11

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-02-05
Form: S-3
Chunk 11
---
 the sufficiency of our cash and cash equivalents to fund our ongoing activities and our ability to continue as a going concern; the impact of current macroeconomic conditions on our operations, ability to access capital, and liquidity. The words “anticipates”, “believes”, “estimates”, “expects”, “intends”, “targets”, “may”, “plans”, “projects”, “potential”, “will”, “would”, “could” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. All such forward-looking statements involve significant risks and uncertainties, including, but not limited to, statements regarding:

| ● | our                                                                                                                               
 plans to develop and potentially commercialize our technology;                                                                    |
| ● | the                                                                                                                               
 timing and cost of our planned investigational new drug application and any clinical trials;                                      |
| ● | the                                                                                                                               
 completion and receipt of favorable results in any clinical trials;                                                               |
| ● | our                                                                                                                               
 ability to obtain and maintain regulatory approval of any product candidate;                                                      |
| ● | our                                                                                                                               
 ability to protect and maintain our intellectual property and licensing arrangements;                                             |
| ● | our                                                                                                                               
 ability to develop, manufacture and commercialize our product candidates;                                                         |
| ● | the                                                                                                                               
 risk of product liability claims, the availability of reimbursement, the influence of extensive and costly government regulation; |
| ● | our                                                                                                                               
 estimates regarding future revenue, expenses capital requirements and the need for additional financing; and                      |
| ● | our                                                                                                                               
 ability to continue as a going concern.                                                                                           |

As more fully described under the heading “Risk Factors” and elsewhere in this prospectus and under “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2023 and any subsequent Quarterly Report on Form 10-Q, which are incorporated by reference into this prospectus in their entirety, many important
factors affect our ability to achieve our stated objectives and to develop and commercialize any product candidates. We may not actually
achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on
our forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause our actual results
to differ materially from those in the forward-looking statements, including, without limitation, the risks and uncertainties set forth
in our filings with the SEC. You should read this prospectus and the documents incorporated by reference herein and